Paradigm Biopharmaceuticals ASX PAR bone marrow lesions hip knee cap ankle iPPS

Paradigm Biopharmaceuticals’ iPPS drug reduces bone marrow lesions in hip, knee caps and ankles

As it advances its injectable Pentosan Polysulfate (iPPS) drug towards commercialisation, Paradigm Biopharmaceuticals (ASX: PAR) has noted a clinically meaningful decrease in bone marrow...
Paradigm Biopharma ASX PAR phase 2b secondary endpoints pentosan polysulfate sodium

Paradigm Biopharma’s knee osteoarthritis trial meets secondary endpoints, launches capital raise

Paradigm Biopharmaceuticals (ASX: PAR) has announced trial patients being treated with its injectable pentosan polysulfate sodium (iPPS) drug for osteoarthritis of the knee have...
Paradigm Biopharmaceuticals ASX PAR IND applicaton mucopolysaccharidosis MPS disease

International symposium sets scene for Paradigm Biopharmaceuticals’ MPS trial

Paradigm Biopharmaceuticals (ASX: PAR) has set its sights on applying to the US Food and Drug Administration (FDA) to begin a clinical trial for...
Paradigm Biopharmaceuticals ASX PAR primary endpoints Phase 2b knee osteoarthritis trial

Paradigm Biopharmaceuticals meets primary endpoints in Phase 2b knee osteoarthritis trial

Paradigm Biopharmaceuticals (ASX: PAR) has confirmed the potential of its injectable pentosan polysulfate sodium (iPPS) drug to be “safe and effective” in treating knee...
Paradigm Biopharmaceuticals PAR ASX knee pain reduction osteoarthritis

Paradigm Biopharmaceuticals reasserts osteoarthritis pain reduction results

Biotechnology company Paradigm Biopharmaceuticals (ASX: PAR) has reasserted its previously published figures relating to pain reduction resulting from its flagship drug treatment Pentosan Polysulfate Sodium...
Paradigm Biopharmaceuticals ASX PAR Pentosan Polysulfate Sodium Icahn School of Medicine at Mount Sinai

Paradigm Biopharmaceuticals to deploy iPPS to treat rare joint disease

Biotechnology company Paradigm Biopharmaceuticals (ASX: PAR) is continuing to expand the gamut of applications for its proprietary Pentosan Polysulfate Sodium (iPPS) drug by signing an agreement...
Paradigm Pharmaceuticals ASX PAR Australian Government research and development tax refund

Australian Government numbs capital expenditure pain for Paradigm Biopharmaceuticals

Biotechnology company Paradigm Biopharmaceuticals (ASX: PAR) has received a further boost in its mission to bring a potentially industry-leading chronic pain medication to the Australian...
Paradigm Biopharma injectable osteoarthritis drug trial reduction chronic pain knee OA

Paradigm’s injectable osteoarthritis drug trial shows major reduction in chronic pain

Australian biotech company Paradigm Pharmaceuticals (ASX: PAR) has reported an average 51.2% reduction in chronic knee pain by a group of osteoarthritis patients being...
Paradigm Biopharmaceuticals ASX PAR Pro Players Elite Network NFL athletes

Paradigm Biopharmaceuticals looks to touchdown its osteoarthritis drug in the United States

Paradigm Biopharmaceuticals (ASX: PAR) has struck a strategic partnership with the Pro Players’ Elite Network (PPEN), a US-based retired professional sporting network comprised of...
Paradigm Biopharmaceuticals ASX PAR chronic pain reduction osteoarthritis

Paradigm Biopharmaceuticals looks to scale summit of chronic pain reduction

Biotech company Paradigm Biopharmaceuticals (ASX: PAR) continues to make progress on its mission of developing a radical shift in reducing chronic joint pain from osteoarthritis. With...
Paradigm Biopharma ASX PAR complete recruitment Ross River virus clinical study trial

Paradigm Biopharma weathers seasonal change to complete recruitment for Ross River virus study

Paradigm Biopharmaceuticals (ASX: PAR) has completed the recruitment stage of its phase 2a clinical trial in participants with persistent ‘Ross River virus (RRV) induced...
Paradigm Biopharmaceuticals ASX PAR osteoarthritis pain reduction knee Pentosan Polysulfate Sodium

Paradigm Biopharma raises the stakes in osteoarthritis pain reduction

Biotech company Paradigm Biopharmaceuticals (ASX: PAR) has announced further progress in its bid to develop a definitive pain reduction treatment for both elite athletes...